Literature DB >> 3011047

Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.

A A Ajayi, N Hockings, J L Reid.   

Abstract

The effect of age on the pharmacodynamic responses to converting enzyme inhibitors, enalapril and enalaprilat was investigated in nine young (22-30 years) and nine sex-matched elderly (65-73 years), healthy volunteers. The groups differed in baseline blood pressure, young 121/64 mmHg, elderly 142/75 mmHg (P less than 0.01), but not in sodium intake or body weight. Both enalapril and enalprilat produced significant falls in blood pressure in both groups but no increase in heart rate in the supine or erect posture. The blood pressure fall was significantly greater in the elderly on both treatments and in both erect and supine posture. The greater fall in blood pressure in the elderly was associated with a more prolonged inhibition of plasma angiotensin converting enzyme activity. The apparent age-related difference in response appears to be due to the difference in baseline blood pressures between the groups. Further study of the usefulness of chronic dosing with angiotensin converting enzyme inhibitors in hypertension in the elderly is indicated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011047      PMCID: PMC1400941          DOI: 10.1111/j.1365-2125.1986.tb05206.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.

Authors:  H Gavras; H R Brunner; G A Turini; G R Kershaw; C P Tifft; S Cuttelod; I Gavras; R A Vukovich; D N McKinstry
Journal:  N Engl J Med       Date:  1978-05-04       Impact factor: 91.245

2.  Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension.

Authors:  F R Bühler; F Burkart; B E Lütold; M Küng; G Marbet; M Pfisterer
Journal:  Am J Cardiol       Date:  1975-10-31       Impact factor: 2.778

3.  Control of enzymatically inactive renin in man under various pathological conditions: implications for the interpretation of renin measurements in peripheral and renal venous plasma.

Authors:  F H Derkx; G J Wenting; A J Man in 't Veld; R P Verhoeven; M A Schalekamp
Journal:  Clin Sci Mol Med       Date:  1978-05

4.  Evaluation of cardiovascular risk in the elderly: the Framingham study.

Authors:  W B Kannel; T Gordan
Journal:  Bull N Y Acad Med       Date:  1978-06

5.  An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients.

Authors:  H Gavras; H R Brunner; J H Laragh; J E Sealey; I Gavras; R A Vukovich
Journal:  N Engl J Med       Date:  1974-10-17       Impact factor: 91.245

6.  Simplified radioimmunoassay for serum aldosterone utilizing increased antibody specificity.

Authors:  J K McKenzie; J A Clements
Journal:  J Clin Endocrinol Metab       Date:  1974-04       Impact factor: 5.958

7.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases.

Authors:  F R Bühler; J H Laragh; L Baer; E D Vaughan; H R Brunner
Journal:  N Engl J Med       Date:  1972-12-14       Impact factor: 91.245

Review 8.  Acute and long-term studies of the mechanisms of action of beta-blocking drugs in lowering blood pressure.

Authors:  K O Stumpe; R Kolloch; H Vetter; W Gramann; F Krück; C Ressel; M Higuchi
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

9.  Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.

Authors:  N Hockings; A A Ajayi; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

10.  Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme.

Authors:  D B Case; J M Wallace; H J Keim; M A Weber; J E Sealey; J H Laragh
Journal:  N Engl J Med       Date:  1977-03-24       Impact factor: 91.245

View more
  5 in total

Review 1.  Angiotensin converting enzyme inhibitors in the elderly.

Authors:  J L Reid
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-17

Review 2.  Optimal dosage of ACE inhibitors in older patients.

Authors:  B Tomlinson
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

3.  The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension.

Authors:  A A Ajayi; H L Elliott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

4.  Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.

Authors:  N Hockings; A A Ajayi; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

5.  Enalapril and hydrochlorothiazide in hypertensive Africans.

Authors:  A A Ajayi; E A Oyewo; G O Ladipo; A Akinsola
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.